These mice are widely used as a transgenic mouse model of AD and develop detectable intraneuronal Aβ accumulation and hyperphosphorylated tau in the brain as well as cognitive impairment at the age of 7–8 months old (Giménez-Llort et al., 2007; Mastrangelo and Bowers, 2008). This evidence concerns the gene MAPT and Alzheimer disease.